Lipid nanoparticles are a vital component of the Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines, playing a key role in protecting and transporting the mRNA effectively to the right place in cells. They are next generation liposomes that use nanotechnology and are well suited to stable and efficient delivery of various therapeutics.
Although mRNA vaccines have received much global interest as they are a new type of drug, lipid nanoparticles have held a recognised position in the mainstream of drug delivery systems (DDS) since the discovery of liposomes in the 1960s. Let us take a closer look at what liposomes are, their evolution and potential for use in other industries.
Want to learn more about lipid nanoparticles and their new applications? Explore our peer reviewed article just published in ACS Nano
Liposomes – the precursor to lipid nanoparticles
Liposomes are closed lipid bilayer vesicles that spontaneously form in water (see fig. 1A) – essentially a fatty capsule. They were discovered in the 1960s and their potential as effective drug delivery systems was almost immediately recognized. Throughout the last few decades scientists have worked on the design of liposomes to control where they act, how long they circulate in the body, and where and when their contents are released.
Liposomes have proven to be an extremely versatile nanocarrier platform because they can transport either hydrophilic drugs within the enclosed aqueous interior, or hydrophobic drugs within the hydrocarbon chain region of the lipid bilayer (see fig. 1B).
They are enormously important in therapeutics, driving medicine forward, and have been used in numerous clinical trials for anticancer, anti-inflammatory, antibiotic, antifungal, and anaesthetic drug delivery as well as for the delivery of gene therapies. In fact, liposomes are the first nanomedicine delivery platform to successfully move from concept to clinical application. There are a number of approved pharmaceutical preparations, for example, Doxil for the delivery of the chemical inhibitor doxorubicin to treat ovarian cancer and Epaxal for the delivery of protein antigen as a hepatitis vaccine, and many more in the pipeline. Understanding how they have been developed will help us unlock potential future uses.
Fig. 1. Schematic representation of: (A) liposome; (B) liposome encapsulating hydrophobic and hydrophilic drugs; (C) immunoliposome functionalized with targeting ligands; (D) sterically stabilized (“stealth”) liposome functionalized with inert polymers such as PEG.
Evolution as a targeted drug delivery system
Despite their benefits, liposomes have a couple of disadvantages: they have a short circulation time in blood stream, are unstable in the human body, and lack selective targeting. There have been several key developments to their construction to overcome these challenges:
To enhance tissue targeting, the liposomes’ surface has been modified with ligands or antibodies which allow the liposome to recognise and bind to specific receptors on the cells (Fig 1C). These are referred to as immunoliposomes.
To improve their longevity in the blood stream, the surface has been coated in biocompatible inert polymers such as PEG (Fig 1D), which goes undetected.
To provide controlled release of the encapsulated drug, scientists have designed stimuli-responsive liposomes which are sensitive to temperature and pH levels. The membrane permeability is enhanced during a stimuli-triggered phase transition of the lipids in formulations.
Lipid nanoparticles have a more complex internal lipid architecture and minimal internal aqueous presence than traditional liposomes. Further enhanced physical stability has been achieved by the development of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), addressing one of the main limitations of emulsion-based formulations. Cubosomes are the most recent improvement which are highly stable nanoparticles formed from a lipid in cubic phase and stabilised by a polymer-based outer corona.
Cationic Lipid Nanoparticles as carriers for nucleic acids
Many of today’s drug molecules are small molecules and biologics. However, increasingly scientists are moving beyond traditional biopharmaceuticals to more complex and specialized therapies including oligonucleotides (RNA, mRNA, siRNA, and DNA-based molecules) that can fight disease at a genetic level.
Nucleic acid-based drugs are a highly interesting new category of biologics that has emerged and a major challenge to their adoption has been ensuring their efficient delivery. This is because the physiochemical properties of the nucleic acids, such as a negative charge and hydrophilicity, prevent passive diffusion across the plasma membrane. They are also susceptible to nuclease degradation. For example, free mRNA, breaks down quickly in the body, thereby diminishing its effectiveness.
To prevent this, and improve stability, advanced technology is required, and this is where lipid nanoparticles come into play. Presently, the most widely used non-viral vector system includes a synthetic positively charged (cationic) lipid. These form stable complexes known as lipoplexes with negatively charged (anionic) nucleic acids. Decorated by positively charged lipids (see fig. 2), nucleic acids are more stable and resistant to nuclease degradation.
Fig. 2. Suggested structures of lipid nanoparticle vaccine carriers: mRNA organized in inverse lipid micelles inside the nanoparticle (A); mRNA intercalated between the lipid bilayers (B1).
Allergic reactions to the mRNA COVID-19 vaccines
Despite their clear advantages for drug delivery, lipid nanoparticles have an unwanted side-effect; they have the potential to induce an allergic reaction, particularly for those who suffer with severe allergies. However, reactions are rare and researchers estimate a rate of 1.1 cases of anaphylaxis for every million first doses of the Pfizer/BioNTech COVID-19 vaccine.
The compositions of the lipid nanoparticles are very similar for the two vaccines (Pfizer/BioNTech and Moderna): an ionizable cationic lipid, a PEGylated lipid, cholesterol, and the phospholipid distearoylphosphatidylcholine (DSPC) as a helper lipid. Scientists believe these reactions are related to the PEG-lipid component of the vaccine as the risk of sensitization appears to be higher with formulations comprising higher-molecule-weight PEG such as PEG3350 – PEG5000. It should be noted that mRNA vaccines contain only MW PEG2000.
Table 1. Constituents of the lipid nanoparticle vehicles of the mRNA vaccines
Lipid Name
Abbreviation
or Lab Code
CAS Registry Number
Pfizer/BioNTech vaccine 1, 21-22
((4-hydroxybutyl)azanediyl) bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
ALC-0315
2036272-55-4
2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
ALC-0159
1849616-42-7
1,2-distearoyl-sn-glycero-3-phosphocholine
DSPC
816-94-4
cholesterol
57-88-5
Moderna vaccine 2, 22-23
heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate
SM-102
2089251-47-6
1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000
PEG2000-DMG
160743-62-4
1,2-distearoyl-sn-glycero-3-phosphocholine
DSPC
816-94-4
cholesterol
57-88-5
Fig. 3. Structures of lipids of the mRNA delivery LNPs
Future applications for Lipid Nanoparticles
While lipid nanoparticles are pushing boundaries for drug delivery, they could also have huge potential in cosmeceuticals, cosmetics and nutrition industries as an alternative carrier to emulsions.
There are many promising applications, for example, they are ideal for dermal applications of cosmetics, giving controlled release of actives and enhanced penetration to increase skin hydration. Furthermore, their excellent physical stability and compatibility with other ingredients means they can be added to existing formulations easily. Using these systems means emulsifiers are unnecessary, enabling scientists to create higher-quality products.
For more information on advanced nanotechnologies and Lipid Nanoparticles sign up to our COVID-19 webinar. You can also explore the additional CAS COVID-19 resources including scientific insights